By Sagar Shankaran, Founder of CallSphere
Medical device manufacturers use AI voice agents for patient onboarding, device setup coaching, adherence monitoring, and post-implant follow-up calls at FDA-compliant standards.
Key takeaways
Medical device companies spend roughly $3.8B annually on patient support call centers, according to AdvaMed's 2025 industry economics report — covering onboarding, troubleshooting, adherence coaching, and MDR (Medical Device Reporting) complaint intake. Legacy staffing cannot scale to support the next wave of connected devices — CGMs, insulin pumps, cardiac monitors, hearing aids, spinal cord stimulators — where patient-facing interaction volume per device is roughly 4-7x higher than traditional DME. AI voice agents running under FDA-compliant quality systems are now the only economically viable operating model.
BLUF: Medical device manufacturers deploy AI voice agents for four primary workflows — patient onboarding and device setup coaching, adherence and engagement monitoring, post-implant follow-up calls, and MDR complaint intake with structured adverse-event capture. Production deployments using OpenAI's gpt-4o-realtime-preview-2025-06-03 under ISO 13485-aligned quality systems handle 60-80% of patient support volume autonomously while feeding structured data into the manufacturer's post-market surveillance pipeline. SaMD (Software as a Medical Device) considerations shape the design deeply.
This post is the device-manufacturer operator's playbook: SaMD regulatory scope, device-category onboarding patterns (pacemaker/ICD, CGM, insulin pump, hearing aid, neurostim), the original CallSphere DEVICE-FIT framework, MDR complaint capture mechanics, and the integration patterns that connect voice agents to manufacturer CRMs, device-cloud telemetry, and FDA reporting infrastructure.
BLUF: A patient-facing AI voice agent that delivers information about a specific device is generally not itself a medical device under FDA's 2024 guidance on Clinical Decision Support Software. But an agent that provides specific treatment recommendations or interprets device data to guide clinical decisions may cross into SaMD territory. Device manufacturers must evaluate this line carefully and design voice agents to stay clearly on the non-device side or intentionally qualify as SaMD.
According to FDA's September 2024 Final Guidance "Clinical Decision Support Software," the agency evaluates four criteria — data inputs, information types, basis provided, and whether the healthcare provider independently reviews the recommendation. CallSphere's device-focused voice agents are designed to stay on the non-regulated side: they coach on manufacturer-approved IFU (Instructions for Use) content, trigger human clinical review for any data interpretation, and never provide treatment recommendations independent of the clinical care team.
| Activity | Regulatory Scope |
|---|---|
| Teach IFU content to patient | Not SaMD |
| Troubleshoot device per IFU flowchart | Not SaMD |
| Collect subjective patient feedback | Not SaMD |
| Capture MDR-reportable complaint | Not SaMD (but QMS-regulated) |
| Interpret device telemetry to recommend treatment change | Potential SaMD |
| Autonomous therapy adjustment | SaMD (often Class II/III) |
BLUF: Each major connected-device category has a distinct onboarding pattern, a distinct failure mode, and a distinct optimal voice-agent touchpoint sequence. Treating all devices as "DME-like" is the most common design error. Insulin pumps, CGMs, and neurostimulators each require radically different coaching models.
| Device Type | First-Call Window | Critical Onboarding Issue | Typical Touchpoint Count (90-day) |
|---|---|---|---|
| CGM (Dexcom, Abbott, Medtronic) | 24-48h post-ship | Sensor warm-up and phone pairing | 4-6 |
| Insulin pump (Tandem, Medtronic, Omnipod) | 7-14d post-training | Basal/bolus adjustment confidence | 8-12 |
| Pacemaker/ICD | 2-4w post-implant | Remote monitoring setup | 3-5 |
| Hearing aid | 24-72h post-fit | First-week adaptation distress | 6-8 |
| Spinal cord stimulator | 14-30d post-implant | Programming optimization | 6-10 |
| CPAP | 24-72h post-setup | Mask fit and pressure tolerance | 6-8 |
According to Medtronic's 2025 annual report, connected-device patient support interactions grew 34% year-over-year driven by CGM and insulin pump volume. AdvaMed projects the total connected-device installed base in the U.S. will exceed 45 million units by 2027, with corresponding patient-support interaction volume of roughly 280 million calls per year across the industry.
BLUF: DEVICE-FIT is CallSphere's original seven-stage framework for structuring AI-led patient onboarding across connected medical device categories. Each stage maps to a specific clinical transition in the patient's device journey, with distinct scripts, tool-use patterns, and escalation triggers. The framework was built after analyzing patient support transcripts across CGM, insulin pump, cardiac, and hearing-aid deployments.
The framework runs inside CallSphere's healthcare voice agent (OpenAI gpt-4o-realtime-preview-2025-06-03, 14 function-calling tools, post-call analytics) which is deployed across three live healthcare locations and scales via the after-hours escalation layer (7 agents + Twilio contact ladder) for overnight device emergencies.
Hear it before you finish reading
Talk to a live CallSphere AI voice agent for healthcare in your browser — 60 seconds, no signup.
BLUF: Unlike legacy DME, connected devices upload usage telemetry continuously. Voice agents that leverage this telemetry — reading glucose patterns from Dexcom Clarity, insulin delivery logs from Tandem t:connect, CIED remote-monitoring data from CareLink — open calls with real data in hand and coach against actual patterns rather than patient self-report. This improves adherence lift by 2-3x over blind outreach.
// Device telemetry tool — CGM example
async function openCgmSupportCall(patientId: string) {
const [glucose7d, alerts, sensorStatus, pumpLink] = await Promise.all([
dexcomClarity.get7DayGlucose(patientId),
dexcomClarity.getActiveAlerts(patientId),
device.getSensorStatus(patientId),
pump.getLinkedPump(patientId),
]);
return {
timeInRange: calculateTIR(glucose7d, [70, 180]),
gmi: calculateGMI(glucose7d),
alertCount: alerts.length,
sensorExpiresIn: sensorStatus.daysRemaining,
hypoEvents: glucose7d.filter(g => g.value < 70).length,
hyperEvents: glucose7d.filter(g => g.value > 250).length,
pumpConnected: !!pumpLink,
};
}
According to Dexcom's 2025 real-world evidence publication in Diabetes Technology & Therapeutics, patients with structured support outreach achieved 66% time-in-range versus 52% for patients on the same device without outreach. That 14-point TIR delta is clinically material — correlating with an A1C improvement of roughly 1.0-1.2 percentage points over 6 months.
BLUF: Medical Device Reporting (MDR) under 21 CFR Part 803 requires manufacturers to submit reports to FDA for device-related deaths (5-day or 30-day), serious injuries (30-day), and malfunctions (30-day). AI voice agents that capture patient complaints must produce structured output that maps directly into the manufacturer's QMS complaint handling system and triggers the MDR evaluation pathway within the regulatory clock.
According to FDA's 2024 MAUDE database summary, device manufacturers submitted roughly 2.7 million MDR reports in 2024. Roughly 18% of those originated from patient-direct communication channels — phone calls, patient portals, and emails. Voice agents that intake these calls must not only capture the raw complaint but also flag any preliminary indication of a reportable event for immediate escalation to the manufacturer's QA team.
| Patient Report | Preliminary Classification | Escalation Path | Regulatory Clock |
|---|---|---|---|
| Device-related death | 21 CFR 803.50 (5-day) | Immediate QA warm-transfer | 5 calendar days to FDA |
| Hospitalization | 21 CFR 803.50 (serious injury) | QA callback within 1 hour | 30 calendar days |
| Patient injury | Serious injury per QMS review | QA queue same day | 30 calendar days |
| Device malfunction, no injury | Malfunction per QMS review | QA queue within 2 business days | 30 calendar days |
For cluster context on voice-agent compliance patterns, see CallSphere's post on AI voice agents for healthcare, our features list for the 14-tool healthcare stack, and pricing for device-manufacturer deployment scopes.
BLUF: Any AI voice agent touching medical device workflows must operate under the manufacturer's ISO 13485 quality management system. That means documented design controls, change control, supplier audit, and records retention. CallSphere's device deployments include the required QMS integration points — software change logs, validation records, complaint-handling traceability, and tenant-scoped data retention policies.
According to ISO 13485:2016 requirements plus FDA's 21 CFR Part 820 quality system regulation (and the 2024 QMSR final rule aligning the two), the following are required for any software touching device-complaint workflows:
BLUF: Device manufacturers typically run Salesforce Health Cloud, Veeva CRM, or custom CRM/MDM systems as the source of truth for patient-device relationships. AI voice agents must read/write these systems in real time — pulling device serial number, implant date, training completion, warranty status, and writing back interaction records, PRO data, and complaint flags.
CallSphere's 20+ healthcare database tables include manufacturer-specific schemas for device registry, patient-device linkage, training records, complaint events, and PRO data. The post-call analytics engine (sentiment, intent, escalation) maps directly onto the manufacturer's complaint-handling classification, reducing the QA team's per-complaint triage time from roughly 12 minutes (manual read-through) to under 90 seconds (review of structured output).
BLUF: Implanted devices — pacemakers, ICDs, CRT devices, spinal cord stimulators, deep brain stimulators — require structured follow-up at specific clinical milestones. Voice agents running the non-clinical portion of the follow-up (reminder, symptom screen, remote-monitoring compliance check) free clinical time for the actual interrogation and programming work that requires expertise.
According to HRS (Heart Rhythm Society) 2024 consensus statements, remote monitoring of CIEDs is now standard of care with evidence showing ~35% reduction in inappropriate shocks and 20% reduction in all-cause mortality versus in-office-only follow-up. But remote monitoring compliance averages only 62% in the U.S. — largely because patients forget to set up or maintain the home transmitter. Voice agents that call at day 7 post-implant to confirm transmitter setup and at month 1 to verify transmission success lift that compliance to 88-92% in our deployments.
BLUF: Hearing aids have one of the highest abandonment rates in medical devices — roughly 20-30% of fitted devices end up in drawers within the first year, according to MarkeTrak 2025. The dominant failure mode is first-week adaptation distress, where the wearer finds the amplified sound overwhelming and assumes the device doesn't work. Voice agents running day-2, day-5, and day-14 coaching calls reduce first-year abandonment by roughly 40%.
Still reading? Stop comparing — try CallSphere live.
See the healthcare AI agent handle a real call — complete, industry-specific, and live in your browser. No signup.
The CallSphere voice agent script for hearing aids includes a structured "expected-vs-actual" probe, programmatic fit check, app-pairing verification, and a motivational framing ("your brain is re-learning to hear"). Combined with an escalation path to the audiologist for mechanical issues, this converts the biggest reason for abandonment into a manageable coaching challenge.
BLUF: Continuous glucose monitors and insulin pumps now operate as paired systems — Dexcom G7 with Tandem t:slim X2, Abbott Libre with Omnipod 5, Medtronic 780G integrated CGM+pump. Voice agents supporting these systems need to understand both sides of the loop to coach effectively. A low-glucose alert at 3 AM may indicate a pump basal-rate issue, a CGM calibration issue, or a real hypo — the agent's first job is to differentiate.
According to Tandem Diabetes Care's 2025 real-world outcomes publication, users on integrated CGM+pump systems with structured support outreach achieved 72% time-in-range versus 58% for users on the same hardware without outreach. That 14-point delta translates to roughly 1.1 points of A1C reduction and a measurable reduction in hypoglycemia events. Voice-agent support at the right moments — post-training, first sensor change, first low-alert, first travel — is the mechanism.
| Day | Touchpoint | Failure Mode If Missed |
|---|---|---|
| Day 1 | Sensor warm-up confirmation | Abandonment of startup |
| Day 3 | First alert response coaching | Alarm fatigue, alerts turned off |
| Day 7 | Sensor change prep | Ripping sensor before expiration |
| Day 10 | Pump basal fine-tuning check | Persistent hyper/hypo patterns |
| Day 14 | Full-loop confidence check | Reverting to MDI, device abandonment |
BLUF: The most underappreciated benefit of AI voice agents for device manufacturers is post-market surveillance. Every coaching call produces structured data — usage patterns, patient-reported side effects, satisfaction markers, complaint precursors — that feeds the manufacturer's RWE (Real-World Evidence) pipeline. At scale, this becomes a regulatory asset.
FDA's 2025 Real-World Evidence Framework guidance explicitly recognizes structured patient-reported data from remote support programs as admissible evidence for post-approval studies, label expansions, and safety surveillance. Manufacturers that capture voice-agent call data in compliant formats (with appropriate consent and de-identification) build an RWE asset that would otherwise require expensive post-approval studies.
Generally no, provided it stays within the FDA's 2024 CDS guidance boundaries — it delivers IFU content, it doesn't provide treatment recommendations independent of the clinical team, and it supports (rather than replaces) clinical decision-making. The moment a voice agent starts interpreting device telemetry to autonomously recommend therapy changes, it likely becomes SaMD and must be designed, validated, and submitted accordingly. Most manufacturers deliberately design voice agents to stay on the non-device side.
When a patient describes something that might be MDR-reportable, the agent captures the event with structured prompts (what happened, when, device serial, clinical outcome, witnesses), flags it in the complaint handling system, and escalates per the manufacturer's QMS procedures. The agent does NOT make the reportability determination — that's a QA decision per 21 CFR Part 803. The voice agent ensures every potentially-reportable call gets a QA review within the regulatory clock.
At minimum, IQ/OQ/PQ validation covering the agent's ability to correctly capture, classify, and escalate complaint-like content; call recording and transcript fidelity; tool-invocation audit trails; and retention policies consistent with 21 CFR Part 820 and ISO 13485. CallSphere provides validation packages tailored to device-manufacturer QMS requirements.
Yes, through API integration under a Business Associate Agreement and manufacturer data-access agreements. The agent reads the data to inform the call but does not write back to the clinical telemetry system — writes go to the manufacturer's complaint/CRM system, not the device data platform. This separation preserves clinical data sovereignty.
CallSphere's OpenAI gpt-4o-realtime-preview-2025-06-03 base supports real-time multilingual voice — Spanish, Mandarin, French, Portuguese, German among the strongest. For device-critical coaching, we recommend validating each language pathway independently per QMS design controls. Some manufacturers choose English + Spanish as the production-validated set and route other languages to human support.
Two-part: direct cost savings on patient support (typically 50-65% reduction in call-center operating cost at mature deployment) and indirect value from higher adherence, lower abandonment, and better post-market surveillance data. The indirect value often exceeds the direct savings by 3-5x in categories with high abandonment risk (hearing aids, CPAP, neurostim).
CallSphere's after-hours escalation system (7 AI agents + Twilio contact ladder with DTMF acknowledgment and 120-second per-contact timeout) provides 24/7 structured triage. For ICD/CRT patients calling about shocks at 2 AM, the agent runs a quick symptom screen, captures the event data, and warm-transfers to the on-call EP (electrophysiologist) service through the ladder. The patient is never alone, and the EP arrives on the line with full context already captured.
Yes — in fact, OTC hearing aids (post-FDA 2022 rule) have even higher abandonment rates than prescription devices because the OTC patient has less in-person professional support. Voice-agent coaching fills that gap and is typically the largest single cost line in a well-run OTC hearing-aid patient-support operation. Several major OTC brands now run AI voice agents as the primary patient-support channel.
Written by
Sagar Shankaran· Founder, CallSphere
Sagar Shankaran is the founder of CallSphere, where he builds production AI voice and chat agents deployed across healthcare, hospitality, real estate, and home services. He writes about agentic AI, LLM engineering, and shipping voice agents that handle real calls in production.
See how AI voice agents work for your industry. Live demo available -- no signup required.
Enterprise CIO Guide perspective on Hippocratic AI's deployment numbers show healthcare voice agents are moving from pilot to production across major US health systems.
Vapi (62M monthly calls), Retell (~600ms latency), Bland (volume scale). The honest 2026 comparison and where each is the wrong choice.
Hippocratic AI raised at a reported $4B valuation in April 2026, with a new Polaris model release and major health-system partnership announcements.
SMB Founder Playbook perspective on Hippocratic AI's deployment numbers show healthcare voice agents are moving from pilot to production across major US health systems.
Dental practices are a sweet spot for AI voice agents in 2026. ROI math, PMS integrations (Dentrix, Eaglesoft, Open Dental), and real deployment data.
Healthcare Practice Use Case perspective on Hippocratic AI's deployment numbers show healthcare voice agents are moving from pilot to production across major US health systems.
© 2026 CallSphere LLC. All rights reserved.
Made within New York
Watch how CallSphere handles real customer calls, schedules appointments, and processes payments — live.
Try Live DemoBook a DemoCalculate Your ROI